News

Nasoni Takes the Lead in Transforming Care for Alzheimer’s and Dementia Patients with $2.4M Federal Grant

Hampton Roads stands at the forefront of innovation by announcing a $2.4 million federal grant to enhance care for Alzheimer’s and dementia patients. This funding, spearheaded by Congresswoman Jen Kiggans, not only highlights the region’s commitment to healthcare but also emphasizes the role of local startups like Nasoni, which are driving the future of patient care.

Nasoni, a forward-thinking Hampton Roads startup known for its innovative faucet designs, is expanding its reach into healthcare with solutions that improve the quality of life for patients facing cognitive challenges. As part of the broader effort supported by the federal grant, Nasoni will play a crucial role in developing practical, user-friendly technologies to assist patients and caregivers alike.

Their patented faucets, designed with ease of use in mind, are particularly valuable for individuals with Alzheimer’s and dementia. With simple features that allow for better access to clean water, Nasoni’s faucets reduce daily stress and improve hydration—an often overlooked but critical aspect of care for aging populations.

Founder Steve Waddell is optimistic about Nasoni’s impact. “Our goal has always been to make life easier through innovative design,” Waddell says. With this grant, we can extend that mission to vulnerable populations in Hampton Roads, providing practical solutions that ease the burdens of care.”

Kiggans, a former geriatric nurse practitioner, recognizes the importance of such local innovations. “Companies like Nasoni are key to revolutionizing the way we support Alzheimer’s and dementia patients. Their commitment to improving everyday tasks like access to clean water aligns with our goal of enhancing patient care in meaningful ways,” she shared during the announcement.

In addition to Nasoni’s contributions, the grant will fund various community-based programs, caregiver training, and healthcare initiatives designed to enhance early detection and personalized care strategies. By combining Nasoni’s innovative products with these expanded services, Hampton Roads is set to become a model for Alzheimer’s and dementia care.

The collaboration between local businesses and healthcare providers underscores the region’s thriving ecosystem of startups and technology. As Nasoni continues to expand its influence, its work will serve as a shining example of how ingenuity can positively impact patient care on a large scale.

This grant not only advances the fight against Alzheimer’s and dementia but also highlights the role of Hampton Roads startups in solving critical healthcare challenges. With Nasoni’s help, the future of care in the region looks brighter than ever.

 

Read more here.

Recent News

07/01/2025

ISOThrive Announces Promising Phase 2 Interim Data for Novel Heartburn Treatment and Appoints Pharma Veteran Mike Walther as Chief Strategy Officer

ISOThrive Inc., a clinical-stage biopharmaceutical company, announced interim results from a Phase 2 study of its lead candidate, ISOT-101, for treatment of Non-Erosive Reflux Disease (NERD). The data showed positive trends in addressing heartburn frequency and symptom severity among proton pump inhibitor (PPI) partial-responders (PR), a patient population with major unmet medical need. These positive

07/01/2025

Gary Lowenthal Joins Focused Ultrasound Foundation’s Council

The Focused Ultrasound Foundation is pleased to welcome Gary Lowenthal to its Council, a dedicated group of goodwill ambassadors who work closely with the Board of Directors and staff to provide advice and assist with raising funds and building awareness. Mr. Lowenthal is a retired educator, entrepreneur, and executive with a career spanning education, international service,

06/25/2025

Liquet Medical Closes Oversubscribed Seed Round to Launch Pilot Study Evaluating Real-Time Hemodynamic Monitoring

Liquet Medical, a clinical-stage medical device company developing the Versus™ Catheter — a first-of-its-kind dual-tipped catheter system cleared by the FDA for controlled and selective infusion of fluids into the pulmonary vasculature and hemodynamic monitoring — announced the successful and oversubscribed close of its Seed funding round, which officially closed in May 2025. The capital